Pub Date : 2023-08-21DOI: 10.19080/jtmp.2023.04.555631
Johanna Weber
In Germany, cancers are on the rise according to health insurance providers. To get an overview on the matter, data from the central agency of health insurance in Germany (Kassenärztliche Bundesvereinigung, KBV) have been analyzed regarding the frequency of cancer-related treatments between 2016 and 2022. Data hint to an increase in cancer-related treatments in German health insurants. Reasons for this could be missed check-up appointments due to lockdowns or other covid-related interventions.
{"title":"Rise in Tumor-Related Treatments within the German Health-Insurance System","authors":"Johanna Weber","doi":"10.19080/jtmp.2023.04.555631","DOIUrl":"https://doi.org/10.19080/jtmp.2023.04.555631","url":null,"abstract":"In Germany, cancers are on the rise according to health insurance providers. To get an overview on the matter, data from the central agency of health insurance in Germany (Kassenärztliche Bundesvereinigung, KBV) have been analyzed regarding the frequency of cancer-related treatments between 2016 and 2022. Data hint to an increase in cancer-related treatments in German health insurants. Reasons for this could be missed check-up appointments due to lockdowns or other covid-related interventions.","PeriodicalId":287475,"journal":{"name":"Journal of Tumor Medicine & Prevention","volume":"2016 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139349865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-03-07DOI: 10.19080/jtmp.2019.03.555621
M. Mahdavi, Mohammad Hossein Yazdi, Pariya Mahin Samadi, S. Haghighat
Immune response patter in the tumor environment determines the outcome of tumor prognosis. Here, tumor-bearing mice were immunized with HPV17E7d vaccine at a distant area of the tumor and balance of cytokines were assessed in the tumor microenvironment. Tumor was established in C57BL/6 mice and mice were vaccinated subcutaneously, three times with two weeks intervals with 20 µg of E7d protein. Two weeks after final immunization, tumor homogenate was prepared and the quantity of IL-2, IL-12, IL-17 and TNF-α cytokines were evaluated with commercial ELISA kits. In addition, lymphocyte proliferation of spleen cells was determined with BRDU method. Results show that immunization with vaccine candidates increased IL-2, IL-12, IL-17 and TNF-α cytokines and lymphocyte proliferation versus un-vaccinated PBS control group. As regard to results of cytokines and lymphocyte proliferation could conclude that tumor microenvironment has been modified by changing cytokines patterns to defeat tumor cell using tumor vaccination even at a distant area of the tumor.
{"title":"Immunization with Hpv16e7d Vaccine to Tumor Bearing Mice: Changes of Cytokines Patters in the Tumor Microenvironment","authors":"M. Mahdavi, Mohammad Hossein Yazdi, Pariya Mahin Samadi, S. Haghighat","doi":"10.19080/jtmp.2019.03.555621","DOIUrl":"https://doi.org/10.19080/jtmp.2019.03.555621","url":null,"abstract":"Immune response patter in the tumor environment determines the outcome of tumor prognosis. Here, tumor-bearing mice were immunized with HPV17E7d vaccine at a distant area of the tumor and balance of cytokines were assessed in the tumor microenvironment. Tumor was established in C57BL/6 mice and mice were vaccinated subcutaneously, three times with two weeks intervals with 20 µg of E7d protein. Two weeks after final immunization, tumor homogenate was prepared and the quantity of IL-2, IL-12, IL-17 and TNF-α cytokines were evaluated with commercial ELISA kits. In addition, lymphocyte proliferation of spleen cells was determined with BRDU method. Results show that immunization with vaccine candidates increased IL-2, IL-12, IL-17 and TNF-α cytokines and lymphocyte proliferation versus un-vaccinated PBS control group. As regard to results of cytokines and lymphocyte proliferation could conclude that tumor microenvironment has been modified by changing cytokines patterns to defeat tumor cell using tumor vaccination even at a distant area of the tumor.","PeriodicalId":287475,"journal":{"name":"Journal of Tumor Medicine & Prevention","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127254868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-07DOI: 10.19080/jtmp.2018.03.555620
Nahla AM Hamed
PV is one of the lower-risk subtypes of MPNs [1] that is characterized primarily by clonal erythrocytosis [2]. It has an annual incidence of 0.21-2.27 per 100,000. Median age at diagnosis is estimated at 71 years. A male preponderance is noted. JAK2 V617F is found in >95% of PV patients and JAK2 exon 12 mutations in ~4% [3]. JAK2 exon 12 mutations such as insertions or deletions are relatively specific to JAK2V617F-negative PV and not found in ET and PMF [4]. JAK2 homozygosity is neither necessary nor sufficient for a PV phenotype as indicated by presence of small or undetectable homozygous clones in some PV patients [5]. Heterozygous mutant erythroblasts of PV patients have distinct transcriptional profiles that precede acquisition of homozygosity and reflect differential activation of phosphorylated STAT1, which modulate erythropoiesis [5]. CALR and MPL have distribution frequency of 0 and 0% [6]. Other mutations (e.g., LNK) have been reported [2]. Co-occurrence of CALR mutation exon 9 with JAK2V617F, usually occurs in less than 1% of PV [4].
{"title":"Polycythemia Vera: Current Therapeutic Approaches","authors":"Nahla AM Hamed","doi":"10.19080/jtmp.2018.03.555620","DOIUrl":"https://doi.org/10.19080/jtmp.2018.03.555620","url":null,"abstract":"PV is one of the lower-risk subtypes of MPNs [1] that is characterized primarily by clonal erythrocytosis [2]. It has an annual incidence of 0.21-2.27 per 100,000. Median age at diagnosis is estimated at 71 years. A male preponderance is noted. JAK2 V617F is found in >95% of PV patients and JAK2 exon 12 mutations in ~4% [3]. JAK2 exon 12 mutations such as insertions or deletions are relatively specific to JAK2V617F-negative PV and not found in ET and PMF [4]. JAK2 homozygosity is neither necessary nor sufficient for a PV phenotype as indicated by presence of small or undetectable homozygous clones in some PV patients [5]. Heterozygous mutant erythroblasts of PV patients have distinct transcriptional profiles that precede acquisition of homozygosity and reflect differential activation of phosphorylated STAT1, which modulate erythropoiesis [5]. CALR and MPL have distribution frequency of 0 and 0% [6]. Other mutations (e.g., LNK) have been reported [2]. Co-occurrence of CALR mutation exon 9 with JAK2V617F, usually occurs in less than 1% of PV [4].","PeriodicalId":287475,"journal":{"name":"Journal of Tumor Medicine & Prevention","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121791846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：